Perdita di grasso e composizione corporea

Survodutide

$925.00

Per vial
$92.50
10 vials per pack
Suggested retail
$277.50
3× markup · per vial
Spedizione gratuita per ordini superiori a 2.000 $
  • Garanzia di consegna Rispedizione gratuita in caso di mancata consegna
  • Purezza ≥99% Produzione diretta dal produttore
  • Certificati di analisi indipendenti Visualizza i COA per questo prodotto →
  • Garanzia di credito negozio Invia qualsiasi risultato COA e ricevi un credito negozio

Survodutide — Glucagon / GLP-1 Dual Agonist Research Peptide

Survodutide (development code BI 456906) is a once-weekly glucagon receptor and GLP-1 receptor dual agonist co-developed by Boehringer Ingelheim and Zealand Pharma. It is the main research peptide for characterizing paired glucagon + GLP-1 signaling, and is currently in Phase 3 trials (SYNCHRONIZE program) for obesity and MASH (metabolic dysfunction-associated steatohepatitis). It sits in the same “multi-receptor GLP-1” family as tirzepatide and retatrutide but pairs GLP-1 with glucagon specifically, not GIP.


Why Glucagon + GLP-1 Matters

The incretin peptides (semaglutide, tirzepatide) work primarily by amplifying insulin release and slowing gastric emptying. Glucagon receptor signaling is different – it increases hepatic energy expenditure and fat oxidation. Pairing glucagon with GLP-1 in a single molecule combines the caloric-intake side (GLP-1) with the energy-expenditure side (glucagon), which is the mechanistic rationale behind survodutide’s design.

Receptor In parole povere, ecco cosa fa
GLP-1 receptor Amplifies insulin release, slows gastric emptying, reduces appetite
Glucagon receptor Increases hepatic energy expenditure and lipid oxidation

Survodutide vs Tirzepatide vs Retatrutide

Three multi-receptor GLP-1 peptides often get compared in the same research literature, so the distinction matters.

Composto Receptors Developer
Survodutide Glucagon + GLP-1 (dual) Boehringer Ingelheim / Zealand Pharma
Tirzepatide GIP + GLP-1 (dual) Eli Lilly
Retatrutide GIP + GLP-1 + Glucagon (triple) Eli Lilly

All three are once-weekly. Survodutide is unique among them for pairing glucagon with GLP-1 as a two-receptor molecule; retatrutide adds GIP on top of the same pair.


Applicazioni di ricerca

Survodutide is used in studies examining:

  • Combined glucagon + GLP-1 signaling in a single molecule
  • Hepatic energy expenditure and fat-oxidation endpoints
  • MASH (metabolic dysfunction-associated steatohepatitis) models
  • Body-composition endpoints vs. GLP-1 monotherapy
  • Comparative research vs. tirzepatide and retatrutide
  • Dose-response characterization through the published Phase 2 range

Specifiche tecniche

Formato Polvere liofilizzata
Purezza ≥99%
Alias BI 456906, glucagon/GLP-1 dual agonist
Taglie disponibili 10 mg
Archiviazione 2-8 °C se non aperto; stabile per oltre 12 mesi
Utilizzo Solo a scopo di ricerca – non destinato all'uso umano

Ricostituzione

Survodutide arrives as a freeze-dried powder and is reconstituted with bacteriostatic water:

Totale in mg nella fiala ÷ ml di acqua aggiunta = mg per ml

Example: a 10mg vial + 2mL of bacteriostatic water = 5mg per mL.

Una volta ricostituito, conservare a una temperatura compresa tra 2 e 8 °C e utilizzare entro 28-30 giorni.


Note sul protocollo

The following values are reference points extracted from published survodutide Phase 2 trials – not instructions. Published protocols use a stepwise escalation approach across several weeks.

  • Starting doses reported in the literature: 0.3mg per administration
  • Escalation pattern observed: Bi-weekly steps through 0.9mg, 1.8mg, 2.7mg, up to 4.8mg
  • Administration frequency in published trials: Once weekly
  • Study durations reported: 46-48 weeks in published Phase 2 trials

Common Questions About Survodutide Research

Is survodutide a GLP-1?

It contains GLP-1 agonism, but it is not a pure GLP-1. Survodutide is a dual agonist – it activates both the glucagon receptor and the GLP-1 receptor. That is what distinguishes it from single-mechanism GLP-1 peptides like semaglutide.

How does survodutide compare to tirzepatide?

They are both once-weekly dual agonists, but they pair GLP-1 with different second receptors. Tirzepatide pairs GLP-1 with GIP (both incretin pathways). Survodutide pairs GLP-1 with glucagon (incretin + energy expenditure). The published endpoints differ as a result.

How does survodutide compare to retatrutide?

Retatrutide is a triple agonist (GIP + GLP-1 + glucagon) and is essentially survodutide’s two receptors plus GIP on top. Head-to-head data does not yet exist in published form; both are in Phase 3.

Is survodutide FDA approved?

No. Survodutide is currently in Phase 3 trials (SYNCHRONIZE program) and is not approved by the FDA for any use. Every vial WWP ships is labeled and sold strictly for laboratory and research use only.

How is survodutide stored?

Le fiale non aperte vanno conservate a una temperatura compresa tra 2 e 8 °C e mantengono la loro stabilità per oltre 12 mesi. Una volta ricostituita con acqua batteriostatica, la soluzione va conservata a una temperatura compresa tra 2 e 8 °C e utilizzata entro 28-30 giorni.


Garanzia di purezza

Ogni lotto ha una purezza pari o superiore al 99%. Inviateci un certificato di analisi (COA) redatto da un ente indipendente e vi accrediteremo un buono acquisto indipendentemente dai risultati riportati.